Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

AcSDKP ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA
  • Species:Multispecies
Please select your region to see available products and prices.
Cat. No. Size Price


RA19007R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA

Applications

Serum, Urine, Plasma

Sample Requirements

1 ml/ plasma and serum sample 25 µl urine sample

Shipping

On ice. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the kit at –20°C. Under these conditions, the kit is stable until expiration date (see label on the box).

Calibration Range

Short immunological reaction: 0,19-25 nM Long immunological reaction: 0,09-12,5 nM

Summary

Research topic

Animal studies

Summary

AcSDKP is a new reliability marker of chronic ACE inhibition. The tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous regulatory factor of hematopoiesis which reverses stem cells and normal early progenitors into S-phase. Angiotensin I-Converting Enzyme (ACE) has two homologous active NH2– and COOH-terminal domains and displays activity toward a broad range of substrates. The AcSDKP has been shown to be hydrolyzed by ACE and to be a preferential substrate for its NH2-terminal active site. In healthy subjects, the acute administration of the ACE inhibitor captopril increases the AcSDKP plasma levels. Several studies aimed to measure plasma or urine AcSDKP levels during treatment with various ACE inhibitors and to confirm its relevance as a marker of ACE inhibition.

Product References (5)

References

  • Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Ménard J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) duringangiotensin-converting enzyme inhibition in humans. Hypertension. 1999Mar;33(3):879-86. PubMed PMID: 10082503. See more on PubMed
  • Azizi M, Ezan E, Nicolet L, Grognet JM, Ménard J. High plasma level ofN-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronicangiotensin-converting enzyme inhibition. Hypertension. 1997 Nov;30(5):1015-9.PubMed PMID: 9369248. See more on PubMed
  • Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M,Corvol P, Ménard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulatorN-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996 Feb 1;97(3):839-44.PubMed PMID: 8609242; PubMed Central PMCID: PMC507123. See more on PubMed
  • Pradelles P, Frobert Y, Créminon C, Ivonine H, Frindel E. Distribution of anegative regulator of haematopoietic stem cell proliferation (AcSDKP) andthymosin beta 4 in mouse tissues. FEBS Lett. 1991 Sep 9;289(2):171-5. PubMedPMID: 1915845. See more on PubMed
  • Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A, Frindel E. Negativeregulator of pluripotent hematopoietic stem cell proliferation in human whiteblood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys ResCommun. 1990 Aug 16;170(3):986-93. PubMed PMID: 2202303. See more on PubMed
Summary References (3)

References to acSDKP

  • Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Menard J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension. 1999 Mar;33 (3):879-86
  • Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996 Feb 1;97 (3):839-44
  • Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, Ezan E. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol. 1999 Dec;34 (7):2072-7
Related Products Docs